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Abstract 
Background: Colorectal cancer is a preventable disease if caught at early stages. This disease is highly aggressive and 
has a higher incidence in African Americans. Several biomarkers and mutations of aggressive tumor behavior have 
been defined such as metastasis-associated in colon cancer 1 (MACC1) that was associated with metastasis in colo-
rectal cancer patients. Here, we aim to assess colon tissue MACC1 protein and circulating MACC1 transcripts in colon 
preneoplastic and neoplastic African American patients.
Methods: Patients’ tissue samples (n = 143) have been arranged on three tissue microarrays for normal (n = 26), 
adenoma (n = 68) and cancer (n = 49) samples. Immunohistochemistry was used to detect MACC1 expression. Blood 
samples (n = 93) from normal (n = 45), hyperplastic (n = 15) and tubular adenoma (n = 33) patients were used to 
assess MACC1 transcripts using qRT-PCR. Distribution of continuous variables was tested between different diagnoses 
with Kruskal–Wallis test. Categorical variables were tested by Chi square test. We assessed the prognostic ability of IHC 
staining by calculating area under receiver operating characteristics curve (ROC) for adenoma and cancer separately. 
Differences between groups in terms of MACC1 transcript levels in plasma were calculated by using non-parametric 
(exact) Wilcoxon-Mann–Whitney tests. We performed all calculations with SPSS, version 21.
Results: In patient tissues, there was a statistically significant difference in MACC1 expression in normal vs. adenoma 
samples (p = 0.004) and normal vs. cancer samples (p < 0.001). There was however no major difference in MACC1 
expression between adenoma vs. cancer cases or tubular adenomas vs tubulovillous adenomas. The area under the 
curve for both normal vs. adenoma and normal vs. cancer cases were 70 and 67 %, respectively. MACC1 expression 
was not correlated to age, gender or anatomical sample location. In patient plasma, MACC1 transcripts in adenoma 
patients were significantly higher than in plasma from normal patients (p = 0.014). However, the difference between 
normal and hyperplastic plasma MACC1 transcripts was not statistically significant.
Conclusion: Metastasis-associated in colon cancer 1 is expressed at early stages of colorectal oncogenesis within the 
affected colonic tissue in this patient cohort. The plasma transcripts can be used to stratify African American patients 
at risk for potential malignant colonic lesions.
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Background
Colorectal cancer (CRC) is the second most common 
cancer causing mortality in Western world [1]. Its inci-
dence is high in African Americans when compared to 
the general population [2–9]. African Americans also dis-
play very advanced and aggressive forms of CRC. There 
is a need to analyze these patients’ tumors for markers of 
such aggressive/advanced pathology [4–6, 8, 10, 11].
The novel gene MACC1 (metastasis associated in colon 
cancer 1) was identified by our group in human CRC 
[12]. Following our initial publication, evidence was pro-
vided that MACC1 regulates fundamental processes like 
proliferation, migration, invasion, and dissemination in 
cell culture by regulating genes important e.g. for metas-
tasis [12–16]. Subcutaneous, orthotopic, and intras-
plenic transplantation of MACC1-expressing tumor cells 
induced tumor growth and metastasis in mice, shRNA 
acting on MACC1 or MACC1 targets decreased metas-
tases [12, 17, 18]. First transgenic MACC1 mice crossed 
with ApcMin mice demonstrated an accelerated adenoma-
carcinoma sequence [19]. In CRC patients, MACC1 is a 
tumor stage-independent predictor for metastasis and 
survival [20–23].
Metastasis associated in colon cancer 1 has been estab-
lished as a prognostic biomarker for a further variety of 
solid cancers such as the gastrointestinal tract (CRC, 
gastric, pancreatic), hepatobiliary, lung, ovarian, breast, 
renal, nasopharyngeal, esophageal, kidney, bladder, gall-
bladder cancers, to glioblastomas and osteosarcomas 
[24–27].
Expression of MACC1 correlates to tumor formation, 
metastases and patient survival, determined in cryo and 
formalin fixed paraffin embedded normal, tumor and 
metastatic tissues from retrospective and prospective 
studies. We also established the detection of circulating 
MACC1 transcripts in cancer patient blood [28, 29]. In 
prospective studies we demonstrated significant correla-
tions of circulating MACC1 transcripts in colon, rectal 
and gastric cancer patients’ plasma with patients’ sur-
vival. Correlations of circulating MACC1 transcripts and 
MACC1 protein expression with survival for lung and 
pancreatic cancer patients were also reported [30, 31].
Since clinical and histopathological classifications 
as well as current tissue-based molecular markers do 
not provide enough information for an early and pre-
cise identification of patients at high-risk for aggres-
sive tumor progression and metastasis formation, it is 
of upmost importance to define molecular biomarkers, 
which will allow the identification of high-risk patients at 
early stages of the disease. MACC1 was found elevated 
at the crucial transition step from adenoma to carcinoma 
as well as in early stages of the disease allowing the early 
identification of high-risk patients [12, 32, 33].
Here we aimed to identify the diagnostic and prog-
nostic potential of MACC1 levels for African American 
patients suffering from colon lesions in different stages 
using immunohistochemistry (IHC) on tissues. We also 
aimed at a non-invasive determination of circulating 
MACC1 transcripts in the plasma of these patients by 
quantitative real time reverse transcriptase-polymerase 
chain reaction (qRT-PCR). For adenoma patients, such 
a MACC1-based blood test was never employed before 
with respect to diagnose adenoma cancer patients vs. 
lesion-free volunteers. We hypothesize that analyzing 
the MACC1 levels in liquid biopsies of African Ameri-
can adenoma patients might be beneficial for prognosis 
of the disease. We demonstrate significant correlations of 
MACC1 levels to early and late stage adenomas reflecting 
the potential use of this marker as a surrogate for tumor 
progression and metastasis risk assessment.
Methods
Aim, design and setting of the study
We aimed to identify the diagnostic and prognostic 
potential of MACC1 levels for African American patients 
suffering from colon lesions in different stages. We 
assessed MACC1 protein using IHC on patient tissues 
samples arranged on microarrays as well as qRT-PCR for 
circulating transcripts in the plasma of these patients.
Tissue specimens, tissue microarrays (TMAs), and IHC
Samples were recruited from pathology department at 
Howard University Hospital. All specimens were col-
lected after written informed consent in accordance 
with the International Conference on Harmonization. 
The study was approved by The Howard University Insti-
tutional Review Board (IRB-06-MRF-39). All patients 
signed a consent form to participate in the study and to 
have the data published without identifiers.
The TMA sections were made from all duplicated sam-
ples and put in three different TMA slides as normal 
matched (n = 26), adenomatous (n = 68) and adenocar-
cinoma (n = 49). A total of 143 samples were stained for 
MACC1 by IHC using an anti-MACC1 antibody. Briefly, 
the TMA sections were deparaffinized by successive 
immersions in xylene (20 min), acetone/Tris 2:1, acetone/
Tris 1:2, Tris/NaCl, aqua dest (5 min each). Epitopes were 
demasked with 10 mM citrate buffer (pH 6, microwave). 
After blocking (5  % goat serum, 30  min), sections were 
incubated with the rabbit polyclonal anti-MACC1 anti-
body (1:50, Sigma HPA020103) for 3 h at room tempera-
ture. Detection was performed using the biotin-based 
ABC kit (Dako; anti-rabbit biotin antibody and anti-bio-
tin-streptavidin-HRP) and diaminobenzidine (1  min) as 
substrate. Counter staining with Mayers haematoxylin 
was done for 1  min. Negative biological controls were 
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performed using non colon tissues as well as duplicates of 
the TMAs’ colon samples to assess reproducibility of the 
results with each given sample. Negative technical con-
trols were carried out by omitting the primary MACC1 
antibody. The stained TMAs were read by two patholo-
gists including one gastrointestinal pathologist (E.L). The 
protein expression was reported as staining 0, 1, 2, 3, 4 
which refer to none, less than 10, 10–25, 25–50, 50–75, 
>75 %, respectively. Sub-cellular staining was reported as 
nuclear, cytoplasmic, or both.
Plasma specimens
Blood specimens from patients and lesion-free volun-
teers were collected after written informed consent in 
accordance with the International Conference on Har-
monization. The study was approved by The Howard 
University Institutional Review Board (IRB-06-MRF-39). 
All patients signed a consent form to participate in the 
study and to have the data published without identifiers.
We collected 45 blood samples of healthy colon lesion-
free patients and 48 blood samples of patients with 
colonic lesions consisting of 33 tubular adenomas (TA) 
and 15 hyperplastic polyps (HPP). All these patients were 
diagnosed at Howard University Hospital, Washington 
DC, from 2011 until 2013. Patients’ data was collected 
from medical records and pathology reports. Exclusion 
criteria were history of cancer of any type. Blood sam-
ples of the included patients were taken at the day of 
diagnosis.
Plasma preparation
Plasma separation was performed from cooled EDTA-
blood at the same day within 7 h post blood taking. This 
was performed on normal (n = 45), TA (n = 33) and HPP 
patients’ blood (n = 15). The freshly collected blood sam-
ples were centrifuged at 1300  rpm for 10  min at 10  °C. 
The supernatant was again centrifuged at 2500  rpm for 
15 min and 4  °C to remove all cell debris. The superna-
tant (plasma) was pipetted into new Eppendorf tubes 
and stored at −80 °C. Samples were blinded so that nei-
ther tumor entity nor disease stage was disclosed during 
analysis.
qRT‑PCR
Isolation of total RNA and qRT-PCR were performed as 
previously described [23]. Briefly, after 30 s at 95 °C, we 
run 45 cycles of 10  s 95  °C, 10  s 62  °C, 10 s 72  °C, and 
a melting curve from 40 °C to 95 °C, using the LightCy-
cler (DNA Master HybProbe kit, Roche Diagnostics). 
Thereby we amplified a 136  bp MACC1-specific PCR 
product with the following primers and probes: for-
ward primer 5′-TTCTTTTGATTCCTCCGGTGA-3′, 
reverse primer 5′-ACTCTGATGGGCATGTGCTG-3′, 
FITC-probe 5′-GCAGACTTCCTCAAGAAATTCTGG 
AAGATCTA-3′, LCRed640-probe 5′-AGTGTTTCAG 
AACTTCTGGACATTTTAGACGA-3′ (syntheses of 
primers and probes: BioTeZ and TIB MolBiol, Berlin, 
Germany). The calibrator cDNA derived from the cell 
lines SW620 (authentication of the cell line by short 
tandem repeat (STR) genotyping, German Collection 
of Microorganisms and Cell Cultures, Braunschweig, 
Germany).
Metastasis-associated in colon cancer 1 mRNA expres-
sions are given as percentage of the mRNA expression 
of a calibrator sample, which was set 100  %. Each sam-
ple was run and calculated in duplicate, the means are 
depicted.
Statistical analyses
Distribution of continuous variables was tested between 
different diagnoses with Kruskal–Wallis test and categor-
ical variables were tested by Chi square test. The agree-
ment between two raters for cytoplasmic percentage 
(C %) staining was measured by calculating the Intraclass 
Correlation Coefficient (ICC). We assessed the prog-
nostic ability of IHC staining by calculating area under 
receiver operating characteristics curve (ROC) for ade-
noma and cancer separately.
Differences between groups in terms of MACC1 tran-
script levels in plasma were calculated by using non-par-
ametric (exact) Wilcoxon-Mann–Whitney tests (because 
of deviations of the distributions from normality and 
small samples). Samples obtained from lesion-free volun-
teers were compared with those from patients with ade-
nomas. P values <0.05 were considered to be significant. 
We performed all calculations with SPSS, version 21.
Results
MACC1 immunohistochemistry discriminates 
between colorectal lesions and normal tissue
One hundred forty-three samples were assessed. Among 
them 26 (18  %) were normal, 68 (48  %) adenomas (30 
tubulovillous (TV) and 38 TA) and 49 (34 %) were CRC. 
Table 1 indicates the demographic and clinical character-
istics of these samples.
Adenoma cases were younger (p =  0.004) and tumor 
size was larger in CRC (<0.001). Two independent 
pathologists (E.L, B.S) reviewed the IHC. Representa-
tive MACC1 stainings are shown for adenomas, non-
metastasized and metastasized CRC (Fig.  1). The ICC 
for % staining between two reviewers was 0.88 (95 % CI 
0.83–0.92) indicating very strong agreement. So we used 
the reading from first pathologist for further analysis. The 
distribution of staining in three groups of samples were 
determined (Table  2). Both adenoma and CRC samples 
had significantly higher staining percentages compared 
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with normal tissue. Further analysis showed that stain-
ing percentage had a area under ROC curve of 70 % (95 % 
CI 59–80 %) to diagnose between adenoma and normal 
samples with highest diagnostic ability in 100 % staining 
(with Sensitivity = 0.84 and Specificity = 0.60) (Fig. 2a). 
Staining % had a area under ROC curve of 67 % (95 % CI 
59–80 %) to diagnose between CRC and normal samples 
with highest diagnostic ability in 100  % (with Sensitiv-
ity =  0.78 and Specificity =  0.60) (Fig.  2b). In all three 
different groups, staining % was not related to gender or 
age. In adenoma and CRC, staining % was not related to 
anatomic location or mass size. A subgroup analysis in 
adenoma samples, indicated that there was no significant 
difference between TV and TA with regard to age, gen-
der, tumor location and size as well as IHC measures.
Elevated circulating MACC1 transcript levels 
in precancerous stages
In order to test for potential difference in levels of circu-
lating MACC1 transcripts in lesion-free-volunteers and 
adenoma patients, we measured MACC1 transcripts in 
normal (n = 45), hyperplastic (n = 15) and tubular ade-
noma (n = 33) patients’ blood. MACC1 transcripts were 
detected in all analyzed samples. MACC1 transcripts 
were detected at a significantly higher level in all ade-
noma patients’ plasma (median 0.6036 MACC1 mRNA 
expression/percent calibrator) when compared to plasma 
of lesion-free volunteers (median 0.4315 MACC1 mRNA 
expression/percent calibrator; p = 0.014). We then tested 
for MACC1 levels in different stages of adenoma devel-
opment. When comparing the normals’ MACC1 tran-
scripts to the group of tubular adenoma patients (n = 33; 
median 0.6045 MACC1 mRNA expression/percent cali-
brator), we also found significantly higher values for the 
adenoma patient group (p = 0.011). However, the differ-
ence between normals (median 0.4315 MACC1 mRNA 
expression/percent calibrator) and hyperplastic patients’ 
plasma (n = 15; median 0.5788 MACC1 mRNA expres-
sion/percent calibrator), MACC1 was not statistically sig-
nificant. This might be due to the relatively small patient 
number in this group (p = 0.239) (Fig. 3a), but might also 
reflect that levels of circulating MACC1 transcript might 
increase during the course from early to late (HPP to 
TA) adenomas. This has to be validated in future analy-
ses employing independent patient cohorts. We observed 
no significant variations of MACC1 levels due to age or 
sex. Taken together, the levels of circulating MACC1 
transcripts in plasma of at least patients with tubular ade-
noma are higher than in lesion-free volunteers and might 
indicate those patients at high risk for tumor progression.
We further established the plasma MACC1 transcripts’ 
diagnostic value using a ROC based analysis. For all com-
parisons, the best cut point was 0.52. When comparing 
normal to HPP/adenoma combined, the AUC (95 % CI) 
was 0.65 (0.53–0.76) with a sensitivity of 65 % and a spec-
ificity of 71 %. For adenoma vs. normal, the AUC (95 % 
CI) was 0.67 (0.54–0.79 with a sensitivity of 67 % and a 
specificity of 71  %. These values were AUC (95  % CI): 
0.60 (0.41–0.79 with a sensitivity of 60 % and a specificity 
of 71 % for the HPP vs. normal comparison (Fig. 3b).
Discussion
Many studies attempted to identify and detect biomark-
ers of CRC and its precursor lesions in non-invasive 
manners that would not require the use of colonoscopy 
or other invasive procedures [34–39]. The present study 
is an attempt in that direction in a population that is 
known to suffer a higher burden of aggressive CRC than 
the general population [4–6, 9, 10, 40–42]. The identifi-
cation of high-risk patients in the pre-malignant stage of 
adenoma by non-invasive technology would potentially 
contribute to early detection and possible intervention to 
alter the process of tumor progression.
Our tissue microarray analysis of normal, adenoma, 
and cancer samples revealed that MACC1 staining was 
not related to gender or age, nor was it related to ana-
tomic location or mass size of adenoma or cancer lesions. 
MACC1 immunohistochemical staining was significantly 
different between normal vs. adenoma, and between 
normal vs. cancer cases, the p values for these differ-
ences were 0.004 and <0.001, respectively. These find-
ings reflect a direct relationship of MACC1 expression 
with the neoplastic transformation at early stages with 
MACC1 being involved in processes other than metasta-
sis alone. Indeed, MACC1 was shown to be involved in 
many processes such as proliferation, tumor-formation 
ability, migration and invasiveness that might begin at 
pre-cancerous stages. This is underlined by the differ-
ence in p values between cancer vs. normal (<0.001) and 
adenoma vs. normal cases (p =  0.004). MACC1 immu-
nohistochemical staining differences between adenoma 
and cancer cases were not statistically significant, In 
line, there was also no significant difference in MACC1 
Table 1 Distribution of  demographic and  clinical charac-
teristics by diagnosis
Normal Adenoma CRC P value
Male gender, no (%) 12 (46 %) 38 (56 %) 23 (48 %) 0.6
Age, median (IQR) 62 (52–74) 59 (52–64) 67 (54–76) 0.004
Age ≥60 years, no (%) 16 (62 %) 27 (43 %) 30 (64 %) 0.06
Location NA 0.07
 Right colon 37 (54 %) 18 (38 %)
 Left colon 31 (46 %) 30 (63 %)
Mass size, median (IQR) NA 1.5 (1.3–2.0) 4.0 (2.5–5.5) <0.001
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Adenoma 1 Adenoma 2 
Normal colon tissue 1
Cancer 1 Cancer 2 
Fig. 1 MACC1 TMA IHC of patients’ tissue samples. Representative MACC1 IHC show cytoplasmic staining for normal colon tissue (intensity = 1), 
for two adenomas (intensity = 2), and for two colorectal cancer samples (Cancer 1: intensity = 3 and Cancer 2, intensity = 4). MACC1 protein 
expression levels were higher in adenoma samples vs. normal tissues (p = 0.004), and were higher in cancer samples vs. normal tissues (p < 0.001). 
No major differences in MACC1 expression levels were found between adenoma vs. cancer cases or tubular adenomas vs tubulovillous adenomas. 
Sections treated without the primary antibody served as controls. Images are presented for 20× magnification
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staining between tubular adenoma and tubulovillous 
adenomas (advanced aggressive histology adenoma). This 
finding points likely to an early onset of expression induc-
tion of MACC1 once the neoplastic process is launched 
in this cohort of African American patients. It is note-
worthy that the adenoma cases were younger (p = 0.004) 
and their lesions smaller in size when compared to CRC 
(<0.001), but still MACC1 could be detected in these 
specimens at statistically significant levels compared to 
normal tissues. Already at this stage, we notice a poten-
tial use of this marker to detect neoplastic lesions with 
potential metastatic features. Indeed, further analysis of 
the staining results led to an area under ROC curve of 
70  % (95  % CI 59–80  %) to diagnose between adenoma 
and normal samples with highest diagnostic ability in 
100  % staining (with Sensitivity  =  0.84 and Specific-
ity = 0.60) (Fig. 2) while the area under ROC curve was 
67 % (95 % CI 59–80 %) to diagnose between CRC and 
normal samples with highest diagnostic ability in 100 % 
(with sensitivity = 0.78 and specificity = 0.60) (Fig. 2).
While most of the published data on MACC1 expres-
sion was done in cancer specimens, our study here 
in precancerous lesions highlights important roles of 
MACC1 at earlier stages. We previously reported sig-
nificantly MACC1 higher levels in tumors and blood of 
early stages CRC patients compared to normal mucosa 
or healthy volunteers, respectively [12, 28]. But although 
we also found MACC1 levels in adenomas there was not 
a statistically significant difference when compared to 
normal mucosa in the analyzed Caucasian cohort [12]. 
Ren and colleagues published a stepwise elevation of 
MACC1 expression in key points of CRC development 
(colorectal adenoma, early-stage invasive and advanced 
adenocarcinoma with liver metastasis) by IHC suggest-
ing that MACC1 may contribute to cancer initiation and 
early invasive growth [33]. However, no comparison of 
MACC1 levels to those of healthy volunteers was shown.
Here we addressed the identification of high-risk 
patients at pre-malignant stages of adenoma focused 
on the African American population known to suffer 
from aggressive CRC. Thus, our findings not only point 
to a role of MACC1 in oncogenesis within the affected 
colonic tissue, but might also be of benefit for at risk 
patients’ population.
These findings on patient tissue prompted us to fur-
ther analyze MACC1 expression at the transcript level 
in blood samples of precancerous colorectal patients. 
To further pinpoint specific occurrence of MACC1 in 
patients’ bloodstream, we included samples from nor-
mal, hyperplastic and tubular adenoma patients. MACC1 
Table 2 Distribution of cytoplasmic percentage (C %) stai-
ning by diagnosis
Normal Adenoma CRC P value
C % staining, 
median (IQR)
95 (80–100) 100 (100–100) 100 (100–100) <0.001
Positive intensity, 
no (%)
23 (92 %) 64 (94 %) 41 (89 %) 0.6
Adenoma vs. normal tissue
0.
00
0.
25
0.
50
0.
75
1.
00
Se
ns
iti
vi
ty
0.00 0.25 0.50 0.75 1.00
1 - Specificity
Area under ROC curve = 0.6950
0.
00
0.
25
0.
50
0.
75
1.
00
Se
ns
iti
vi
ty
0.00 0.25 0.50 0.75 1.00
1 - Specificity
Area under ROC curve = 0.6684
Cancer vs. normal tissue
a
b
Fig. 2 MACC1 cytoplasmic percentage (C %) staining to diagnose 
between adenoma vs. normal and cancer vs. normal tissues. Both 
adenoma and CRC samples had significantly higher staining percent-
ages compared with normal tissue. Adenoma vs CRC cases had 
similar MACC1 staining (ROC (95 % CI) 0.47 (0.40–0.55, not shown). 
a Staining % had a area under ROC curve of 70 % (95 % CI 59–80 %) 
to diagnose between adenoma and normal samples with highest 
diagnostic ability in 100 % staining (with Sensitivity = 0.84 and Speci-
ficity = 0.60). b Staining % had a area under ROC curve of 67 % (95 % 
CI 59–80 %) to diagnose between CRC and normal samples with 
highest diagnostic ability in 100 % staining (with Sensitivity = 0.78 
and Specificity = 0.60)
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transcripts were detected at a significant higher level 
in the combined group of hyperplastic and tubular 
adenoma patients’ plasma when compared to lesions-
free patients’ plasma (p  =  0.014). Significance was also 
reached when comparing lesion-free patients’ MACC1 
transcripts to the group of tubular adenoma patients 
(p =  0.011). This very important finding highlights that 
MACC1 blood levels can be used to distinguish patients 
with neoplastic transformation before reaching the carci-
noma state. The difference between normals and hyper-
plastic patients’ plasma MACC1 transcripts was not 
statistically significant in our study (Fig. 3). This finding 
might be due to a lack of expression of MACC1 at the 
hyperplastic level or to the small number of such cases 
(n = 15) included in this comparison. Thus, validation of 
our findings in independent patient cohorts, ideally aris-
ing from African American as well as other e.g. Cauca-
sian populations, is desired. It is worth noting however 
the ROC curve for MACC1 transcripts for HPP vs. Nor-
mal was fair (AUC = 0.60 with a sensitivity of 60 % and 
a specificity of 71 %). These values were much more sig-
nificant in the case of adenoma vs. normal comparison 
(AUC = 0.67 with a sensitivity of 67 % and a specificity 
of 71  %). These findings highlight the potential use of 
MACC1 plasma transcripts as a diagnostic tool to stratify 
patients with potential metastatic colonic lesions. This 
non-invasive quantitative detection overcomes the limi-
tation of snapshot analyses in tissues. We found higher 
levels of circulating MACC1 transcripts in CRC patients 
including those of early stages linked to shorter survival 
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a
Fig. 3 MACC1 transcripts in normal, hyperplastic (HPP) and tubular adenoma (TA) patients’ plasma. a MACC1 transcripts were detected in all meas-
ured normal (n = 45), HPP (n = 15) and TA (n = 33) patients’ plasma. MACC1 transcript levels were higher in all adenoma patients’ plasma (median 
0.6036 MACC1 mRNA expression/percent calibrator) vs. normal patients’ plasma (median 0.4315 MACC1 mRNA expression/percent calibrator; 
p = 0.014). MACC1 transcript levels were also higher in TA patients plasma (median 0.6045 MACC1 mRNA expression/percent calibrator) vs. normal 
patients’ plasma (p = 0.011). However, MACC1 transcript levels were not significantly higher in HPP patients plasma (median 0.5788 MACC1 mRNA 
expression/percent calibrator) vs. normal patients’ plasma (p = 0.239). b Area under the curve was calculated for the diagnostic value of plasma 
MACC1 transcripts for Normal vs. HPP, Normal vs. Adenoma and for Normal vs. Adenoma/HPP combined
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[28]. Circulating MACC1 transcripts have also been used 
as biomarker in the context of non-small cell lung cancer 
and gastric cancer [29, 30]. However, its use at precancer-
ous stages has not been reported before our study.
In the future, the multimarker combinations of circulat-
ing MACC1 transcripts with further blood-based mRNA 
markers [43, 44] as well as with blood-based miRNA 
markers [45] might be beneficial for the improvement of 
diagnosis and prognosis of colon adenoma patients.
Conclusion
We report a significant MACC1 protein expression 
induction in colon adenoma patients’ tissue and a sig-
nificant induction of circulating MACC1 transcripts 
in colon adenoma patients’ blood, compared to lesion-
free volunteers. Our findings might be very relevant for 
the use of MACC1 for prognostication of unfavorable 
tumor progression and metastatic potential of colorectal 
lesions.
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